BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn

Core Points - BrainStorm Cell Therapeutics Inc. announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer, while Dr. Stacy Lindborg steps down as Co-CEO to join the Board of Directors [1][2] - The management changes are strategic as the company prepares for a registrational Phase 3b trial for NurOwn®, its investigational cell therapy for amyotrophic lateral sclerosis (ALS) [1][2] - Dr. Dagher has over 20 years of experience in clinical research and development, previously serving as Chief Medical Officer at Enveric Biosciences and holding leadership roles at GSK, Sanofi/Genzyme, and LabCorp/Covance [2][3] Company Overview - BrainStorm Cell Therapeutics is a developer of autologous adult stem cell therapeutics for neurodegenerative diseases, specifically focusing on ALS [4] - The company holds rights to the NurOwn® technology platform, which has received Orphan Drug designation from the FDA and EMA for ALS treatment [4] - BrainStorm has completed a Phase 3 trial for ALS, supported by grants from the California Institute for Regenerative Medicine and the ALS Association [4][5]